Table 2.

Vosoritide follow-up protocol from the French Early Access Program [39]

Data elements of interest	Day 0 visit (Treatment start)	Teleconsultation (Month 1)	Month 3	Month 6 and every 6 months	End of follow-up
Documentation of achondroplasia	√
Demographics	√
Medical and surgical history	√
Clinical exam	√		√		√
Vital signs including blood pressure	√			√	√
Detailed anthropometric and morphological measurements	√			√ (annual)
X-ray of left hand and one knee				√ (annual)
Tanner stages	√			√ (annual)
Medical and surgical events (incl. ACH-related interventions or investigations including blood test results)			√	√	√
Administration, prescribing and adherence information for vosoritide	√	√	√	√	√
Visits healthcare professional	√		√	√
Adverse event collection	√	√	√	√	√
Concomitant and new medications	√	√	√	√	√

ACH achondroplasia